A pharmaceutical composition for treating skin inflammation, and a preparation method and application thereof

By preparing a capsule composed of multiple traditional Chinese medicines, a multi-target synergistic approach was used to treat skin inflammation, which solved the problems of unclear composition of traditional Chinese medicine compound preparations and safety issues of Western medicine, and achieved a safe and effective treatment effect for skin inflammation.

CN122440753APending Publication Date: 2026-07-24ZUNYI TRADITIONAL CHINESE MEDICINE HOSPITAL
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202610801267.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-06-04
Publication Date
2026-07-24

AI Technical Summary

Technical Problem

The chemical composition and mechanism of action of existing traditional Chinese medicine compound preparations for treating skin inflammation are unclear, and existing Western medicine treatments have safety and cost issues.

Method used

A traditional Chinese medicine composition consisting of Dictamnus dasycarpus root bark, Tribulus terrestris, Smilax glabra rhizome, Kochia scoparia fruit, Lonicera japonica flower, Angelica dahurica root, Rehmannia glutinosa root, Phellodendron chinense bark, Paeonia suffruticosa root bark, Lithospermum erythrorhizon root, Cicadae periostracum, Glycyrrhiza uralensis root, Gardenia jasminoides fruit, and Sophora flavescens root is formulated into capsules. It exerts its anti-skin inflammation effect through a multi-component, multi-target, and multi-pathway synergistic mode. Specifically, it downregulates the expression of inflammatory factors such as TNF-α, IL-1β, COX-2, and IL-6, upregulates the expression of anti-inflammatory factor IL-10, and inhibits the activation of the PI3K-Akt signaling pathway.

Benefits of technology

It achieves a skin inflammation treatment with clearly defined components, a clear mechanism, and high safety, significantly reduces skin lesion symptoms in psoriasis model rats, lowers PASI scores, and has no obvious toxic side effects, making it suitable for industrial production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122440753A_ABST
    Figure CN122440753A_ABST
Patent Text Reader

Abstract

The present application relates to traditional Chinese medicine composition and its application in the field of skin inflammation diseases, and discloses a kind of drug composition for treating skin inflammation and its preparation method and application.The composition is prepared from white fungus, tribulus terrestris, smilax glabra, kochia scoparia, honeysuckle, baishiy, rehmannia glutinosa, oak, peony, radix lithospermi, periostracum cicadae, licorice, gardenia and sophora flavescens.The UPLC-Q-TOF-MS identification contains 110 kinds of components;Animal experiments show that it can significantly reduce psoriasis skin lesions, down-regulate TNF-alpha, IL-1beta and IL-6, up-regulate IL-10, and inhibit PI3K-Akt pathway.The present application has clear components, clear mechanism and definite curative effect, and can be used for preparing medicine for treating psoriasis, chronic urticaria and senile pruritus.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to traditional Chinese medicine compositions and their application in the field of skin inflammatory diseases, specifically to a pharmaceutical composition for treating skin inflammation, its preparation method, and its application. Background Technology

[0002] Skin inflammation is a very common clinical manifestation of skin diseases, mainly including psoriasis (psoriasis vulgaris), atopic dermatitis, contact dermatitis, chronic urticaria, and senile pruritus. As the largest organ in the human body, the skin is the body's first line of defense against invading pathogens and the maintenance of internal homeostasis. When the skin is affected by internal and external factors such as infection, allergen stimulation, physical damage, contact with chemicals, or autoimmune disorders, an inflammatory response can be induced, characterized by erythema, edema, papules, exudation, desquamation, itching, and pain.

[0003] Currently, clinical treatment strategies for skin inflammation follow the principles of tiered and individualized approaches, mainly including two categories: local treatment and systemic treatment. Topical treatment primarily involves topical medications, with topical corticosteroids being the first-line treatment. These corticosteroids exert their anti-inflammatory, anti-proliferative, and immunosuppressive effects by inhibiting phospholipase A2, blocking the arachidonic acid metabolic pathway, and reducing the synthesis and release of pro-inflammatory mediators such as prostaglandins and leukotrienes. However, long-term or inappropriate use of corticosteroids can lead to skin atrophy, telangiectasia, pigmentation changes, secondary infections, steroid-dependent dermatitis, and systemic absorption-related adverse reactions. Calcineurin inhibitors (such as tacrolimus and pimecrolimus) are alternative options suitable for delicate areas such as the face and neck, but some patients may experience local burning or stinging sensations, and the risk of lymphoma with long-term use remains controversial. Crizoborone, as a novel phosphodiesterase-4 inhibitor, has shown some efficacy, but its long-term safety requires further observation.

[0004] In terms of systemic treatment, oral antihistamines are mainly used to relieve itching symptoms, but their effect on controlling inflammation itself is limited. Oral or injectable glucocorticoids are suitable for acute severe cases, but they are not suitable for long-term use due to systemic adverse reactions (hyperglycemia, osteoporosis, water and sodium retention, immunosuppression, etc.). Traditional immunosuppressants such as cyclosporine and methotrexate can be used for refractory moderate to severe cases, but they have risks such as liver and kidney toxicity, bone marrow suppression, and hypertension. Clinical application requires regular monitoring of blood drug concentration and organ function. Biologics such as anti-TNF-α monoclonal antibodies, anti-IL-17 monoclonal antibodies, and anti-IL-4 / 13 monoclonal antibodies have strong targeting and definite efficacy, but they are expensive, require injection, and have risks of infection, allergic reactions, and potential tumors, which limits their widespread use in a large number of patients.

[0005] Traditional Chinese medicine (TCM) has a long history and unique advantages in treating skin inflammation. TCM believes that skin inflammation often falls under the category of "wind-heat and blood dryness syndrome," with the pathogenesis involving internal damp-heat, intense heat toxicity, and blood heat generating wind. Treatment should focus on clearing heat, cooling the blood, dispelling wind, and relieving itching. However, existing TCM compound preparations generally suffer from problems such as unclear chemical components, ambiguous mechanisms of action, and inadequate quality control, hindering their modernization and international recognition.

[0006] Therefore, developing a traditional Chinese medicine compound preparation for treating skin inflammation with clearly defined components, a clear mechanism, definite efficacy, and high safety has significant clinical importance and market value. Summary of the Invention

[0007] The present invention aims to provide a pharmaceutical composition for treating skin inflammation, its preparation method and application, to solve the technical problems of unclear chemical composition and unclear mechanism of action of existing traditional Chinese medicine compound preparations, and to provide a new drug for the safe, effective and multi-target synergistic treatment of skin inflammation.

[0008] Objective 1: The present invention adopts the following technical solution: a pharmaceutical composition for treating skin inflammation, mainly made from the following raw materials in parts by weight: 20-40 parts of Dictamnus dasycarpus root bark, 30-50 parts of Tribulus terrestris root, 15-30 parts of Smilax glabra rhizome, 15-30 parts of Kochia scoparia fruit, 50-70 parts of Lonicera japonica flower, 10-30 parts of Angelica dahurica root, 30-50 parts of Rehmannia glutinosa root, 15-30 parts of Phellodendron chinense bark, 30-50 parts of Paeonia suffruticosa root bark, 15-30 parts of Lithospermum erythrorhizon root, 15-30 parts of Cicadae periostracum, 8-20 parts of Glycyrrhiza uralensis root, 10-30 parts of Gardenia jasminoides fruit, and 10-30 parts of Sophora flavescens root.

[0009] Specifically, the preferred pharmaceutical composition includes 30 parts of Dictamnus dasycarpus root bark, 40 parts of Tribulus terrestris root, 24 parts of Smilax glabra rhizome, 24 parts of Kochia scoparia fruit, 60 parts of Lonicera japonica flower, 20 parts of Angelica dahurica root, 40 parts of Rehmannia glutinosa root, 24 parts of Phellodendron chinense bark, 40 parts of Paeonia suffruticosa root bark, 24 parts of Lithospermum erythrorhizon root, 24 parts of Cicadae periostracum, 14 parts of Glycyrrhiza uralensis root, 20 parts of Gardenia jasminoides fruit, and 20 parts of Sophora flavescens root.

[0010] Specifically, the dosage form of the pharmaceutical composition is preferably a capsule.

[0011] Objective 2: The method for preparing the aforementioned pharmaceutical composition includes the following steps: (1) Weigh each raw material according to the weight parts and mix them; (2) Crush the mixed raw materials and pass them through an 80-mesh sieve to obtain fine powder; (3) Mix the fine powder evenly; (4) Fill the well-mixed fine powder into the capsule shell to make capsules.

[0012] Specifically, each capsule contains 0.4g of contents, with a tolerance of ±10%.

[0013] Objective 3: The use of the pharmaceutical composition in the preparation of a drug for treating skin inflammation.

[0014] Specifically, the skin inflammation is psoriasis, chronic urticaria, or senile pruritus.

[0015] Specifically, the skin inflammation is psoriasis vulgaris.

[0016] Objective 4: The application of the pharmaceutical composition in the preparation of anti-inflammatory drugs exerts a therapeutic effect by downregulating the expression of inflammatory factors TNF-α, IL-1β, COX-2, and IL-6, upregulating the expression of anti-inflammatory factor IL-10, and inhibiting the activation of the PI3K-Akt signaling pathway.

[0017] Working principle of the invention: This invention demonstrates that the pharmaceutical composition exerts its anti-skin inflammation effect through a synergistic mechanism involving multiple components, multiple targets, and multiple pathways. Specifically: Chemical composition basis: UPLC-Q-TOF-MS analysis revealed that the pharmaceutical composition of this invention contains 110 chemical components, mainly including glycosides (41), flavonoids (19), alkaloids (18), organic acids (16), coumarins (6), and terpenes (5). Among them, geniposide, paeoniflorin, quercetin, and glycyrrhizic acid are the main active ingredients.

[0018] Targets of action: Network pharmacology analysis shows that the active ingredients of the pharmaceutical composition of the present invention can act on 192 skin inflammation-related targets, including core targets such as IL-6, TNF-α, AKT1, STAT3, and GAPDH.

[0019] Signaling pathway: KEGG enrichment analysis showed that the PI3K-Akt signaling pathway is a key pathway for the treatment of skin inflammation by the pharmaceutical composition of the present invention.

[0020] Molecular Mechanism: Molecular docking verification showed that geniposide has strong binding activity (binding energy < -8 kcal / mol) with core targets such as AKT1, GAPDH, and TNF-α. The pharmaceutical composition of this invention reduces inflammation, repairs the skin barrier, and improves skin lesion symptoms by downregulating the expression of pro-inflammatory factors TNF-α, IL-1β, COX-2, and IL-6, upregulating the expression of anti-inflammatory factor IL-10, and inhibiting the abnormal activation of the PI3K-Akt signaling pathway.

[0021] Compared with the prior art, the present invention has the following beneficial effects: The composition is clearly defined: 110 chemical components were identified using UPLC-Q-TOF-MS technology, clarifying the material basis of the drug's efficacy.

[0022] The mechanism is clear: through network pharmacology and molecular docking technology, the synergistic mechanism of "multi-component-multi-target-multi-pathway" was elucidated, providing a scientific basis for clinical application.

[0023] Definite therapeutic effect: Animal experiments have confirmed that the drug composition of the present invention can significantly reduce the skin lesion symptoms (erythema, scaling, thickening) in psoriasis model rats, and significantly reduce the PASI score in a dose-dependent manner.

[0024] High safety: This invention is a pure traditional Chinese medicine compound preparation, which does not contain chemical drugs such as glucocorticoids and immunosuppressants, and has no obvious toxic side effects with long-term use.

[0025] Simple preparation: It adopts traditional crushing, mixing and capsule filling process, which is simple to operate and suitable for industrial production.

[0026] The therapeutic effects of the drug composition described in this formula include: clearing heat and cooling blood, dispelling wind and relieving itching. It is used for wind-heat and blood dryness syndrome, with symptoms such as red skin, itching, rash, dry mouth, dark yellow urine, red tongue, yellow coating, and wiry, slippery or rapid pulse, as well as for psoriasis vulgaris, chronic urticaria, and senile pruritus with the above symptoms. Attached Figure Description

[0027] Figure 1 The figures show the skin lesion changes in the model group from day 1 to day 7 in the experimental examples of this invention; ① to ⑦ in the figure represent the number of days respectively; Figure 2 The changes in skin lesions during drug intervention for 1-7 days in the experimental examples of this invention; Figure 3 To detect the levels of inflammatory factors in rat blood and skin tissue using ELISA, the control group in the figure represents (blank group), m (model group), y (positive control group), d (low-dose group), z (medium-dose group), and g (high-dose group). In the figure, p < 0.05 indicates a significant difference compared to the blank group. p < 0.01 compared to the model group. The data conforms to a normal distribution and passes the normality test; Figure 4 Western blot was used to detect the expression of inflammatory factors in skin tissue; Figure 5 To detect the differential expression of inflammatory cytokine proteins in skin tissue using Western blot; Control (blank group), m (model group), y (drug-treated group), d (low-dose group), z (medium-dose group), g (high-dose group). In the figure, p < 0.05, compared to the blank group, the model group... p < 0.01 indicates a comparison with the model group. The data conforms to a normal distribution and passes the normality test; Figure 6 In it, A is the Venn diagram of the intersection of the component targets and the disease targets, and B is the structural diagram of the potential target PPI network; Figure 7 is the visualization diagram of the core targets (31 nodes, 413 edges); Figure 8 In it, A is the GO function enrichment bar chart, and B is the KEGG pathway enrichment bubble chart; Figure 9 is the compound network regulation diagram of drug-component-disease-target; the dark red triangle is skin inflammation; the red rhombus is the traditional Chinese medicine in Fuerkang Capsule, Light Yellow Sophora Root: Sophora flavescens; Licorice Root: Glycyrrhiza uralensis; Gardenia Fruit: Gardenia jasminoides Ellis; Tree Peony Bark: Moutan Cortex; Angelica Root: Angelica dahurica; Amur Cork-Tree Bark: Phellodendron amurense Rupr.; Rehmannia glutinosa: Rehmannia glutinosa; Lonicera japonica: Lonicera japonica; orange is the chemical component; green is the gene target; Figure 10 is the visualization diagram of the molecular docking of geniposide with AKT1, GAPDH, and TNF; A is the docking result of Geniposide with AKT1 protein; B is the docking result of Geniposide with GAPDH protein; C is the docking result of Geniposide with TNF protein. Detailed implementation manners

[0028] The following is a further detailed description through specific implementation manners: Table 1 The drugs and reagents used in the experiments of this invention are as follows

[0029] Example 1: A drug composition for treating skin inflammation (named Fuerkang Capsule)

Prescription

[0030]

Production prescription

[0031] [Preparation Method] Grind the above fourteen ingredients into a fine powder, sift, mix well, and fill into capsules to obtain the final product.

[0032] [Characteristics] This product is a capsule, the contents of which are light grayish-brown; it has a foul odor and a slightly bitter taste.

[0033]

Identification

[0034] (2) Take 1.5g of the contents of this product, add 5ml of methanol, let stand for 12 hours, filter, and use the filtrate as the test solution. Separately, take chlorogenic acid reference standard and add methanol to prepare a solution containing 1mg per ml as the reference solution. Perform thin-layer chromatography (Chinese Pharmacopoeia 2015 Edition, Part IV, 0502). Take 15ul of each of the above two solutions and spot them separately on the same silica gel H thin-layer plate with sodium carboxymethyl cellulose as binder. Use butyl acetate-formic acid-water (7:2.5:2.5) as the developing solvent, develop, remove, air dry, and examine under ultraviolet light (365nm). In the chromatogram of the test sample, spots of the same color appear at the corresponding positions as in the chromatogram of the reference standard.

[0035] [Inspection] It should comply with all relevant regulations under the section on capsules (Chinese Pharmacopoeia 2015 Edition, Part IV, 0103).

[0036]

Functions and Indications

[0037] [Dosage and Administration] For oral administration. Take 4 capsules each time, 3 times a day.

[0038]

Specifications

[0039] 3. Observation Indicators (1) PASI score: The skin lesions on the back of the rats were observed daily. The erythema, scales and thickening were scored from 0 to 4 points respectively. The sum of the three was the total PASI score.

[0040] (2) Detection of inflammatory factors (ELISA method): Blood was collected from the orbital cavity 2h and 4h after administration, serum was separated, and the levels of IL-6, IL-1β and TNF-α were detected.

[0041] (3) Western blot detection: Take back skin tissue and detect the expression of NF-κB, IL-1β, TNF-α, iNOS, COX-2 and NLRP3 proteins.

[0042] 4. Experimental Results 4.1 Skin lesion manifestations and PASI score Figure 1 As shown, on day 2 of modeling, bright red, scattered erythema and a small amount of scales began to appear on the backs of rats in the model group; on day 4, the area of ​​erythema increased and scales appeared; on day 6, the scales were distributed in layers and were significantly thickened; on day 7, the scales basically covered the entire back, rolled up and fell off in flakes. The rats in the model group exhibited typical psoriasis-like skin lesions.

[0043] Figure 2 As shown, after treatment, the skin lesions in the positive control group showed the most significant improvement, approaching the normal skin condition of the control group. The high-dose group of Fuerkang capsules demonstrated superior therapeutic effects compared to the medium- and low-dose groups, exhibiting a dose-dependent effect. This indicates that Fuerkang capsules can significantly reduce psoriatic-like skin lesions.

[0044] 4.2 Serum inflammatory factor levels (ELISA)

[0045] The results showed that ( Figure 3 ): 1. The psoriasis model rats induced by imiquimod cream showed obvious systemic inflammatory dysregulation, manifested by elevated levels of pro-inflammatory factors (TNF-α, IL-1β), which is consistent with the pathological mechanism of psoriasis, and the model was successfully established.

[0046] 2. Fuerkang capsules can significantly regulate the serum inflammatory factor levels in psoriasis model rats. By downregulating the secretion of pro-inflammatory factors such as TNF-α, IL-1β, and IL-6, it effectively balances the body's inflammatory microenvironment and reduces systemic inflammatory response. Moreover, this regulatory effect shows a clear dose-dependent effect, with the high-dose group showing the best results.

[0047] 3. The ELISA test results and the skin tissue WB test results corroborated each other, further confirming that Fuerkang capsules can play a role in treating psoriasis by regulating the expression of inflammatory factors and improving immune disorders. This provides important serological evidence for the molecular mechanism of Fuerkang capsules in treating psoriasis and also provides experimental support for its clinical application in the treatment of psoriasis.

[0048] 4.3 Skin tissue protein expression (Western blot) Figure 4 , Figure 5 As shown, Western blot results indicated that, compared with the model group, the expression of NF-κB, IL-1β, TNF-α, iNOS, COX-2, and NLRP3 proteins in the skin tissue of each dose group of Fuerkang capsules was significantly decreased (p < 0.05 or p < 0.01), with the most significant decrease in the high-dose group.

[0049] Conclusion: Fuerkang capsules exert their anti-psoriasis effect by inhibiting the NF-κB signaling pathway and NLRP3 inflammasome activation, and downregulating the expression of pro-inflammatory factors.

[0050] Experimental Example 2: Identification of Chemical Composition of Fuerkang Capsules (UPLC-Q-TOF-MS) 1. Experimental Methods Preparation of test solution: Take 0.5g of the contents of Fuerkang capsules, add 10mL of 50% methanol, extract by sonication for 3min, centrifuge at 13000rpm for 15min, and inject the supernatant.

[0051] Liquid chromatography conditions: Waters ACQUITY UPLC HSS T3 column (2.1×100mm, 1.8μm); mobile phase A was 0.1% formic acid in water, and mobile phase B was acetonitrile; gradient elution; column temperature 30℃; injection volume 2μL; flow rate 0.3mL / min.

[0052] Mass spectrometry conditions: ESI positive and negative ion mode; scan range m / z 100-1500.

[0053] 2. Experimental Results A total of 110 chemical components were identified in Fuerkang capsules, including:

[0054] Compound type distribution: 41 glycosides, 19 flavonoids, 18 alkaloids, 16 organic acids, 6 coumarins, 5 terpenes, and 5 others.

[0055] Representative components: geniposide, paeoniflorin, quercetin, glycyrrhizic acid, chlorogenic acid, matrine, paeonol, etc.

[0056] Experimental Example 3: Network Pharmacology and Molecular Docking Research 1. Method Active ingredient screening: Lipinski rules (SwissADME) Target prediction: SwissTargetPrediction database Disease targets: GeneCards, OMIM database (keyword "Skin Inflammation") PPI Network: STRING database + Cytoscape 3.9.1 Enrichment Analysis: DAVID Databases (GO and KEGG) Molecular docking: AutoDock Vina 2. Results 2.1 Intersecting Targets: 578 drug component targets, 1699 disease targets, and 192 intersecting targets ( Figure 6 A).

[0057] 2.2 PPI Network: A PPI network containing 190 nodes and 3709 edges was constructed. Figure 6 B), 31 core targets were selected based on degree value ( Figure 7 The top 5 by degree are: IL6, TNF, GAPDH, AKT1, and STAT3.

[0058] 2.3 GO functional enrichment: A total of 1120 items were enriched, including 822 biological processes, 102 cellular components, and 196 molecular functions. Figure 8 A).

[0059] 2.4 KEGG pathway enrichment: The PI3K-Akt signaling pathway showed the highest enrichment significance. Figure 8 B).

[0060] 2.5 “Drug-Ingredient-Disease-Target” Network: A complex network was constructed containing 9 medicinal herbs, 38 active ingredients, and 192 targets. Figure 9 Geniposide exhibits the highest topological importance in the network, suggesting it is a key active ingredient.

[0061] 2.6 Molecular docking: The binding energies of geniposide with AKT1, GAPDH, and TNF-α were all below -8 kcal / mol ( Figure 10 This indicates strong binding activity.

Claims

1. A pharmaceutical composition for treating skin inflammation, characterized in that, It is mainly made from the following raw materials in parts by weight: 20-40 parts of Dictamnus dasycarpus root bark, 30-50 parts of Tribulus terrestris root, 15-30 parts of Smilax glabra rhizome, 15-30 parts of Kochia scoparia fruit, 50-70 parts of Lonicera japonica flower, 10-30 parts of Angelica dahurica root, 30-50 parts of Rehmannia glutinosa root, 15-30 parts of Phellodendron chinense bark, 30-50 parts of Paeonia suffruticosa root bark, 15-30 parts of Lithospermum erythrorhizon root, 15-30 parts of Cicadae periostracum, 8-20 parts of Glycyrrhiza uralensis root, 10-30 parts of Gardenia jasminoides fruit, and 10-30 parts of Sophora flavescens root.

2. The pharmaceutical composition according to claim 1, characterized in that, The preferred pharmaceutical composition consists of 30 parts of Dictamnus dasycarpus root bark, 40 parts of Tribulus terrestris root, 24 parts of Smilax glabra rhizome, 24 parts of Kochia scoparia fruit, 60 parts of Lonicera japonica flower, 20 parts of Angelica dahurica root, 40 parts of Rehmannia glutinosa root, 24 parts of Phellodendron chinense bark, 40 parts of Paeonia suffruticosa root bark, 24 parts of Lithospermum erythrorhizon root, 24 parts of Cicadae periostracum, 14 parts of Glycyrrhiza uralensis root, 20 parts of Gardenia jasminoides fruit, and 20 parts of Sophora flavescens root.

3. The pharmaceutical composition according to claim 1 or 2, characterized in that: The preferred dosage form is capsules.

4. The method for preparing the pharmaceutical composition according to claim 1 or 2, characterized in that: Includes the following steps: (1) Weigh each raw material according to the weight parts and mix them; (2) Crush the mixed raw materials and pass them through an 80-mesh sieve to obtain fine powder; (3) Mix the fine powder evenly; (4) Fill the well-mixed fine powder into the capsule shell to make capsules.

5. The preparation method according to claim 4, characterized in that: Each capsule contains 0.4g of contents, with a tolerance of ±10%.

6. Use of the pharmaceutical composition of claim 1 or 2 in the preparation of a medicament for treating skin inflammation.

7. The application according to claim 6, characterized in that, The skin inflammation is psoriasis, chronic urticaria, or senile pruritus.

8. The application according to claim 6, characterized in that, The skin inflammation described is psoriasis vulgaris.

9. The use of the pharmaceutical composition according to claim 1 or 2 in the preparation of an anti-inflammatory drug, characterized in that, The pharmaceutical composition exerts its therapeutic effect by downregulating the expression of inflammatory factors TNF-α, IL-1β, COX-2, and IL-6, upregulating the expression of anti-inflammatory factor IL-10, and inhibiting the activation of the PI3K-Akt signaling pathway.